Christian Schmidt-Lauber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Schmidt-Lauber has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Achim Jörres
Medizinische Klinik I Köln-Merheim, Klinik für Nephrologie, Transplantationsmedizin und internistische Intensivmedizin, Kliniken der Stadt Köln gGmbH, Köln, Deutschland
1 shared publication - Amin Elfanish
Department of Medicine I, Nephrology, Transplantation and Medical Intensive Care, University Witten/Herdecke Medical Center Cologne-Merheim, 51109 Cologne, Germany
1 shared publication - Elion Hoxha
Zentrum für Innere Medizin, lll. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
1 shared publication - Gerald Stefan Braun
Division of Nephrology and Immunology, RWTH Aachen University, Aachen, Germany
1 shared publication - Jan Boeckhaus
Clinic for Nephrology and Rheumatology, University Medical Center Göttingen, Goettingen, Germany
1 shared publication - Jan-Eric Turner
III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 9 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (14) , 3049
Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study
In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824).
- 9 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (14) , 3049
Open AccessValidation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study
In COVID-19, guidelines recommend a urinalysis on hospital admission as SARS-CoV-2 renal tropism, post-mortem, was associated with disease severity and mortality. Following the hypothesis from our pilot study, we now validate an algorithm harnessing urinalysis to predict the outcome and the need for ICU resources on admission to hospital. Patients were screened for urinalysis, serum albumin (SA) and antithrombin III activity (AT-III) obtained prospectively on admission. The risk for an unfavorable course was categorized as (1) “low”, (2) “intermediate” or (3) “high”, depending on (1) normal urinalysis, (2) abnormal urinalysis with SA ≥ 2 g/dL and AT-III ≥ 70%, or (3) abnormal urinalysis with SA or AT-III abnormality. Time to ICU admission or death served as the primary endpoint. Among 223 screened patients, 145 were eligible for enrollment, 43 falling into the low, 84 intermediate, and 18 into high-risk categories. An abnormal urinalysis significantly elevated the risk for ICU admission or death (63.7% vs. 27.9%; HR 2.6; 95%-CI 1.4 to 4.9; p = 0.0020) and was 100% in the high-risk group. Having an abnormal urinalysis was associated with mortality, a need for mechanical ventilation, extra-corporeal membrane oxygenation or renal replacement therapy. In conclusion, our data confirm that COVID-19-associated urine abnormalities on admission predict disease aggravation and the need for ICU (ClinicalTrials.gov number NCT04347824).